Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

0R19 LN​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

0R19 LN​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Becton Dickinson & Co(0R19 LN)

$217.90+2.701.25%(Market Closed · 18:42:44 UTC · (15 min delay))
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Becton Dickinson & Co(0R19 LN)

$217.90+2.701.25%(Market Closed · 18:42:44 UTC · (15 min delay))
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingEmployees

Financials & Metrics

FinancialsChartingEmployees

Becton Dickinson & Co — Company Profile

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
LN
CEO
Thomas E. Polen Jr.
Headquarters

Becton Dickinson & Co — Company Profile

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
LN
CEO
Thomas E. Polen Jr.
Headquarters
Franklin Lakes, NJ, US
IPO Date
Nov 5, 2014
Employees
72,000
Website
www.bd.com

Key Metrics

Price
$176.96
Market Cap
$50.44B
Revenue (TTM)
$4.71B
Net Income (TTM)
$-311000000.00
EPS (TTM)
-1.11
P/E (TTM)
44.32
P/B (TTM)
2.09
Dividend Yield
33.42%
ROE (TTM)
-1.29%
ROA (TTM)
-0.61%
Operating Margin
13.28%
Beta
0.59

Dividends

Last Dividend
$1.05
Last Yield
0.33%

Summary

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Website
www.bd.com
Location
Franklin Lakes, NJ, US
Phone201 847 6800
Employees72,000
CEOThomas E. Polen Jr.
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateNov 5, 2014

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3K)

Expand
  • Form 144Goette Roland10 Nov
  • Form 4Huffines Robert Luther10 Nov
  • Form 4Byington Carrie L10 Nov
  • Form 4Polen Thomas E Jr9 Nov
  • Form 144Polen Thomas E Jr5 Nov
  • 8-KResults of Operations and Financial Condition5 Nov
  • Form 4Feld Michael27 Oct
  • Form 144Feld Michael26 Oct
  • Form 4Feld Michael29 Sep
  • Form 144Feld Michael28 Sep
  • Form 4Roque Vitor3 Sep
  • Form 4Feld Michael27 Aug
  • Form 144Feld Michael26 Aug
  • Form 4Feld Michael24 Aug
  • Form 144Byrd Richard20 Aug
  • Form 4Polen Thomas E Jr14 Aug
  • Form 144Polen Thomas E Jr13 Aug
  • Form 4Goette Roland12 Aug
  • Form 144Goette Roland11 Aug
  • SC 13GBECTON DICKINSON & CO7 Aug

Mentions in Filings

  • … s representatives. On February 9, 2026 (the “Closing Date”), the Company completed the acquisition (the “BDS Business Acquisition”) of the Biosciences and Diagnostic Solutions business (the “BDS Business”) of <strong>Becton, Dickinson and Company</strong> (“BD”). The transaction was structured as a Reverse Morris Trust transaction, where the BDS Business was spun off to BD shareholders and simultaneously merged with Augusta SpinCo Corporation, a wholly-owned sub …
    WATERS CORP /DE/Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … oducts is unaffected. We face intense competition in virtually all of our product lines, from, among others, Baxter, Ethicon (a Johnson & Johnson Company), Medtronic, Abbott Laboratories, Edwards Lifesciences, <strong>Becton, Dickinson and Company</strong>, Integra Life Sciences, LifeNet Health, Corcym, Anteris Technologies, Elutia (formerly Aziyo Biologics), Cook Medical, Gore & Associates, Terumo, LeMaitre Vascular, Maquet, Pfizer, BioCer Entwicklungs-GmbH, and …
    ARTIVION, INC.Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • On February 13, 2018, Becton, Dickinson, and Company (“BD”) filed a lawsuit against the Company alleging trade secret misappropriation and copyright infringement. On October 6, 2020, the Company entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which the Company and BD agreed to a mutual release of all claims against each other as of the date thereof (the “BD Agreement”). Additionally, BD granted Cytek a non-exc …
    Cytek Biosciences, Inc.Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • … mpany's acquisitions within Restructuring charges, separation costs, and other. 9 --- Table of Contents 4. DISCONTINUED OPERATIONS The Company sold (i) its Critical Care product group (“Critical Care”) to <strong>Becton, Dickinson and Company</strong> (“BD”) in September 2024 and (ii) a business that was not focused on implantable medical innovations for structural heart diseases (the “non-core product group”) in December 2025 (collectively, the “discontinue …
    Edwards Lifesciences CorpBecton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • *Results for the acquired Biosciences and Diagnostic Solutions businesses (the “BDS Businesses”) for the prior year comparable period are the quarterly results for the Biosciences and Diagnostic Solutions business units for the three months ended September 30, 2025, as reported in Exhibit 99.1 of the current report on Form 8-K filed by Becton, Dickinson and Company (“BDX”) with the Securities and Exchange Commission (“SEC”) on November 6, 2025. T …
    WATERS CORP /DE/Becton Dickinson & Co·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·3 Nov
  • … opharmaceutical company, and PMV Pharmaceuticals, Inc., a precision oncology company. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and <strong>Becton, Dickinson and Company</strong>. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a …
    Aspen Neuroscience, Inc.Becton Dickinson & Co·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·30 Oct

Key Stats

Trading

Px/Chg 1D$176.96 / +0.28%
Avg Volume1.24K
Beta0.59
Mkt Cap50.44B
FD Mkt Cap53.98B

Float

Shrs Out/Float285.01M / 274.69M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$2.00B

Current Valuation

EV66.70B
EV/EBITDA12.63
EV/Sales3.12
P/B2.09
P/S2.36
FCF Yield0.94%
ROE-1.29%
ROA-0.61%
Current Ratio0.94

Dividend

Cash$1.05
Yield33.42%
Yield (TTM)33.42%

Estimates

P/E44.32
Est P/E0.00
Est EPS2.78
Est PEG0.00

Valuation

Metric5Yr AvgDec '22Dec '23Dec '24Dec '25Oct '26
PRICE-BASED RATIOS
Price / Earnings15.6041.2946.8838.63113.37-162.17
Price / Sales6.193.893.593.269.4910.70
Price / Book Value2.492.912.702.542.202.09
Price / Free Cash Flow52.1944.2232.8921.4355.78106.63
ENTERPRISE VALUE METRICS
Enterprise Value79,883.688,867.284,557.785,073.974,219.366,699.8
Enterprise Value / Sales8.014.714.364.2212.6014.15
Enterprise Value / EBITDA34.0720.7319.7818.1957.3654.27
Enterprise Value / EBIT66.4840.6740.0033.59111.61106.55

Financials

Full Financials
Millions USD5Yr CAGR (%)Sep '21Sep '22Sep '23Sep '24Sep '25
INCOME STATEMENT
Revenue3.4%19,131.018,870.019,372.020,178.021,839.0
Gross Income3.6%8,631.08,477.08,823.09,125.09,924.0
EBITDA3.9%4,252.04,287.04,275.04,677.04,957.0
EBIT3.7%2,161.02,185.02,114.02,533.02,495.0
Net Income-5.4%2,092.01,779.01,484.01,705.01,678.0
EPS (Diluted)-4%6.855.885.105.865.83
BALANCE SHEET
Cash & ST Inv-22.7%2,404.01,167.01,424.02,301.0859.0
Total Assets67%53,866.052,934.052,780.057,286.055,325.0
Total Liabilities-21%30,189.027,652.026,984.031,396.029,936.0
Total Shareholder Equity1.8%23,677.025,282.025,796.025,890.025,390.0
CASH FLOW
Net Operating Cash Flow-7.3%4,647.02,634.02,989.03,798.03,430.0
Cap Ex-10.7%-1,194.0-973.0-874.0-725.0-760.0
Free Cash Flow-6.2%3,453.01,661.02,115.03,073.02,670.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)217.80
Basic Shares285.01
Market Cap62,075.8
Diluted Shares275.16
Fully Diluted Shares Outstanding275.16
Fully Diluted Market Cap59,929.4
+Consolidated Debt16,808.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-863.0
−Short-term Investments-1.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value78,020.8

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

L3harris Technologies, Inc. /DE/

LHX US

Franklin Lakes, NJ, US
IPO Date
Nov 5, 2014
Employees
72,000
Website
www.bd.com

Key Metrics

Price
$176.96
Market Cap
$50.44B
Revenue (TTM)
$4.71B
Net Income (TTM)
$-311000000.00
EPS (TTM)
-1.11
P/E (TTM)
44.32
P/B (TTM)
2.09
Dividend Yield
33.42%
ROE (TTM)
-1.29%
ROA (TTM)
-0.61%
Operating Margin
13.28%
Beta
0.59

Dividends

Last Dividend
$1.05
Last Yield
0.33%

Summary

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Website
www.bd.com
Location
Franklin Lakes, NJ, US
Phone201 847 6800
Employees72,000
CEOThomas E. Polen Jr.
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateNov 5, 2014

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3K)

Expand
  • Form 144Goette Roland10 Nov
  • Form 4Huffines Robert Luther10 Nov
  • Form 4Byington Carrie L10 Nov
  • Form 4Polen Thomas E Jr9 Nov
  • Form 144Polen Thomas E Jr5 Nov
  • 8-KResults of Operations and Financial Condition5 Nov
  • Form 4Feld Michael27 Oct
  • Form 144Feld Michael26 Oct
  • Form 4Feld Michael29 Sep
  • Form 144Feld Michael28 Sep
  • Form 4Roque Vitor3 Sep
  • Form 4Feld Michael27 Aug
  • Form 144Feld Michael26 Aug
  • Form 4Feld Michael24 Aug
  • Form 144Byrd Richard20 Aug
  • Form 4Polen Thomas E Jr14 Aug
  • Form 144Polen Thomas E Jr13 Aug
  • Form 4Goette Roland12 Aug
  • Form 144Goette Roland11 Aug
  • SC 13GBECTON DICKINSON & CO7 Aug

Mentions in Filings

  • … s representatives. On February 9, 2026 (the “Closing Date”), the Company completed the acquisition (the “BDS Business Acquisition”) of the Biosciences and Diagnostic Solutions business (the “BDS Business”) of <strong>Becton, Dickinson and Company</strong> (“BD”). The transaction was structured as a Reverse Morris Trust transaction, where the BDS Business was spun off to BD shareholders and simultaneously merged with Augusta SpinCo Corporation, a wholly-owned sub …
    WATERS CORP /DE/Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … oducts is unaffected. We face intense competition in virtually all of our product lines, from, among others, Baxter, Ethicon (a Johnson & Johnson Company), Medtronic, Abbott Laboratories, Edwards Lifesciences, <strong>Becton, Dickinson and Company</strong>, Integra Life Sciences, LifeNet Health, Corcym, Anteris Technologies, Elutia (formerly Aziyo Biologics), Cook Medical, Gore & Associates, Terumo, LeMaitre Vascular, Maquet, Pfizer, BioCer Entwicklungs-GmbH, and …
    ARTIVION, INC.Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • On February 13, 2018, Becton, Dickinson, and Company (“BD”) filed a lawsuit against the Company alleging trade secret misappropriation and copyright infringement. On October 6, 2020, the Company entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which the Company and BD agreed to a mutual release of all claims against each other as of the date thereof (the “BD Agreement”). Additionally, BD granted Cytek a non-exc …
    Cytek Biosciences, Inc.Becton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • … mpany's acquisitions within Restructuring charges, separation costs, and other. 9 --- Table of Contents 4. DISCONTINUED OPERATIONS The Company sold (i) its Critical Care product group (“Critical Care”) to <strong>Becton, Dickinson and Company</strong> (“BD”) in September 2024 and (ii) a business that was not focused on implantable medical innovations for structural heart diseases (the “non-core product group”) in December 2025 (collectively, the “discontinue …
    Edwards Lifesciences CorpBecton Dickinson & Co·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • *Results for the acquired Biosciences and Diagnostic Solutions businesses (the “BDS Businesses”) for the prior year comparable period are the quarterly results for the Biosciences and Diagnostic Solutions business units for the three months ended September 30, 2025, as reported in Exhibit 99.1 of the current report on Form 8-K filed by Becton, Dickinson and Company (“BDX”) with the Securities and Exchange Commission (“SEC”) on November 6, 2025. T …
    WATERS CORP /DE/Becton Dickinson & Co·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·3 Nov
  • … opharmaceutical company, and PMV Pharmaceuticals, Inc., a precision oncology company. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and <strong>Becton, Dickinson and Company</strong>. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a …
    Aspen Neuroscience, Inc.Becton Dickinson & Co·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·30 Oct

Key Stats

Trading

Px/Chg 1D$176.96 / +0.28%
Avg Volume1.24K
Beta0.59
Mkt Cap50.44B
FD Mkt Cap53.98B

Float

Shrs Out/Float285.01M / 274.69M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$2.00B

Current Valuation

EV66.70B
EV/EBITDA12.63
EV/Sales3.12
P/B2.09
P/S2.36
FCF Yield0.94%
ROE-1.29%
ROA-0.61%
Current Ratio0.94

Dividend

Cash$1.05
Yield33.42%
Yield (TTM)33.42%

Estimates

P/E44.32
Est P/E0.00
Est EPS2.78
Est PEG0.00

Valuation

Metric5Yr AvgDec '22Dec '23Dec '24Dec '25Oct '26
PRICE-BASED RATIOS
Price / Earnings15.6041.2946.8838.63113.37-162.17
Price / Sales6.193.893.593.269.4910.70
Price / Book Value2.492.912.702.542.202.09
Price / Free Cash Flow52.1944.2232.8921.4355.78106.63
ENTERPRISE VALUE METRICS
Enterprise Value79,883.688,867.284,557.785,073.974,219.366,699.8
Enterprise Value / Sales8.014.714.364.2212.6014.15
Enterprise Value / EBITDA34.0720.7319.7818.1957.3654.27
Enterprise Value / EBIT66.4840.6740.0033.59111.61106.55

Financials

Full Financials
Millions USD5Yr CAGR (%)Sep '21Sep '22Sep '23Sep '24Sep '25
INCOME STATEMENT
Revenue3.4%19,131.018,870.019,372.020,178.021,839.0
Gross Income3.6%8,631.08,477.08,823.09,125.09,924.0
EBITDA3.9%4,252.04,287.04,275.04,677.04,957.0
EBIT3.7%2,161.02,185.02,114.02,533.02,495.0
Net Income-5.4%2,092.01,779.01,484.01,705.01,678.0
EPS (Diluted)-4%6.855.885.105.865.83
BALANCE SHEET
Cash & ST Inv-22.7%2,404.01,167.01,424.02,301.0859.0
Total Assets67%53,866.052,934.052,780.057,286.055,325.0
Total Liabilities-21%30,189.027,652.026,984.031,396.029,936.0
Total Shareholder Equity1.8%23,677.025,282.025,796.025,890.025,390.0
CASH FLOW
Net Operating Cash Flow-7.3%4,647.02,634.02,989.03,798.03,430.0
Cap Ex-10.7%-1,194.0-973.0-874.0-725.0-760.0
Free Cash Flow-6.2%3,453.01,661.02,115.03,073.02,670.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)217.80
Basic Shares285.01
Market Cap62,075.8
Diluted Shares275.16
Fully Diluted Shares Outstanding275.16
Fully Diluted Market Cap59,929.4
+Consolidated Debt16,808.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-863.0
−Short-term Investments-1.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value78,020.8

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

L3harris Technologies, Inc. /DE/

LHX US